Scarica l'app Stockscreener
3.42
5.88%
0.19
Dopo l'orario di chiusura:
3.38
-0.04
-1.17%
Precedente Chiudi:
$3.23
Aprire:
$3.28
Volume 24 ore:
257.95K
Relative Volume:
0.11
Capitalizzazione di mercato:
$592.15M
Reddito:
$42,000
Utile/perdita netta:
$-12.38M
Rapporto P/E:
-12.98
EPS:
-0.2634
Flusso di cassa netto:
$-9.61M
1 W Prestazione:
+17.93%
1M Prestazione:
+66.83%
6M Prestazione:
+116.46%
1 anno Prestazione:
+76.29%
Intervallo 1D:
$3.20
$3.47
Intervallo di 1 settimana:
$2.81
$3.47
Portata 52W:
$0.91
$4.20
Entera Bio Ltd Stock (ENTX) Company Profile
Nome
Entera Bio Ltd
Settore
Industria
Telefono
972-2-532-7151
Indirizzo
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
3.42 | 557.52M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-22 | Iniziato | Aegis Capital | Buy |
Entera Bio Ltd Borsa (ENTX) Ultime notizie
Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1%Here's Why - MarketBeat
Entera Bio CEO Miranda Toledano to speak at Canaccord Genuity conference - scanx.trade
Entera (ENTX) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Reported Period - vinanet.vn
Entera (ENTX) Results Review: EPS Misses Its Estimate; Market Move: Shares Finish 4.84% Up in the Current Update - vinanet.vn
Entera Bio appoints new chief medical officer - The Globe and Mail
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Entera Bio appoints Riccardo Camisasca as chief medical officer - Investing.com
Entera Bio Names New Chief Medical Officer Ahead of EB613 Phase 3 Start - Minichart
Form 8K Entera Bio Ltd. For: 18 August By Investing.com - Investing.com Nigeria
Entera Bio appoints Riccardo Camisasca as chief medical officer By Investing.com - Investing.com Canada
A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial - Stock Titan
Renaissance Technologies LLC Buys 365,441 Shares of Entera Bio Ltd. $ENTX - MarketBeat
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement - MarketBeat
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7% - MarketBeat
Entera Bio at Canaccord Genuity: oral osteoporosis push advances By Investing.com - Investing.com Canada
Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants - Stock Titan
Entera Bio shares slip as Q2 loss comes in wider than expected - Yahoo Finance
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com Nigeria
Entera Bio misses Q2 estimates, reports wider loss - Investing.com
Entera Bio (ENTX) Holds Near $2.86 as Shares Consolidate Between Support and ResistanceStock Buy Zone - vinanet.vn
Entera Bio Ltd. (ENTX) stock price, news, quote and history - au.finance.yahoo.com
Entera Bio (NASDAQ:ENTX) Upgraded to Sell at Wall Street Zen - MarketBeat
Entera Bio (NASDAQ:ENTX) Announces Earnings Results - MarketBeat
Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million - scanx.trade
Entera Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Entera Bio Reports Q2 2026 Loss and $275 Million Private Placement - Moomoo
Entera Bio Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Entera Bio (ENTX) awards 180,000 options to Chief of R&D - Stock Titan
Entera Q2 2026 earnings: Phase 3 preparation widened the loss - TradingKey
ENTX: FDA-aligned Phase 3 for EB613 and $275M financing secure pipeline progress and cash runway - TradingView
Entera Bio Ltd. Q2 2026: Revenue $0M, Net loss $7.31M, EPS ($0.14) — 10-Q Summary - TradingView
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entera Bio Sees Funding Sufficient Into 2030 >ENTX - Moomoo
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entera Bio data selected for ASBMR plenary session - PharmaTimes
ENTX Q2'26 Earnings: EPS estimate is (0.08) USD - TradingView
Entera Bio (ENTX): Longitude entities report 4.6% ownership, Seven Fleet 4.1% - Stock Titan
Entera Bio (NASDAQ:ENTX) Trading Down 2.1%Here's What Happened - MarketBeat
BVF Partners Wins Board Designation Rights at Entera Bio with 9.99% Stake - TradingView
Seven Fleet funds disclose 4.1% Entera Bio (ENTX) stake and shared voting power - stocktitan.net
Entera Bio (ENTX) sees BVF build 9.99% stake after $275M financing - Stock Titan
Entera Bio (ENTX) stake of 12.25M shares reported by TCG Crossover - stocktitan.net
Vivo Opportunity group (NASDAQ: ENTX) discloses 12.3M-share holding in Entera Bio - Stock Titan
Entera Bio’s EB613 data selected for plenary poster at ASBMR - Investing.com
Entera Bio Ltd. (IL0011429839.SG) Stock Forum & Discussion - Yahoo! Finance Canada
Entera Bio’s EB613 data selected for plenary poster at ASBMR By Investing.com - Investing.com Australia
Entera Bio’s oral bone-building candidate selected for ASBMR plenary - Stock Titan
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Weekly Recap: Entera Bio $275M placement and director resignations - TradingView
Entera Bio Ltd Azioni (ENTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Entera Bio Ltd Azioni (ENTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Mar 05 '26 |
Buy |
1.23 |
10,000 |
12,300 |
188,098 |
| Rubin Steven D | Director |
Feb 12 '26 |
Buy |
1.49 |
5,000 |
7,450 |
15,000 |
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):